HuaTeng Biotech In Vivo Models: Complex Surgical & Gene-Edited Large Animals

Created on 10.23

HuaTeng Biotech In Vivo Models: Complex Surgical & Gene-Edited Large Animals

Every promising molecule, implant, catheter and cell therapy eventually meets the same unforgiving test: does it work in a living system that behaves like a human patient? That question is why in vivo models sit at the center of translational research, and why the quality of the model so often determines whether a program advances to first-in-human trials or quietly stalls. Rodent studies can illuminate mechanism, but they cannot reproduce the scale, hemodynamics, anatomy and healing behavior of a human heart, artery, joint or abdominal cavity. Large animal in vivo models bridge that gap, giving sponsors realistic tissue geometry, realistic surgical access, realistic device torque and realistic immune responses. HuaTeng Biotech has built its preclinical platform around that bridge, combining surgical craftsmanship with regulated quality systems so that data generated in pigs, dogs, sheep and rabbits can genuinely support regulatory submissions. This article examines how the company designs, executes and documents these studies, and what sponsors should look for when selecting a partner for complex surgical and gene-edited large animal work.
The practical value of a well-designed in vivo model becomes clear when you consider what regulators and investors actually ask for. They ask whether the device performs under realistic loading, whether the biologic reaches the target tissue at a therapeutic exposure, whether the wound closes without adverse reaction, and whether the findings reproduce across animals and across sites. Answering those questions requires more than an animal facility; it requires surgical expertise, anesthesia and perioperative critical care, imaging, histopathology and disciplined documentation working in a single workflow. HuaTeng Biotech deliberately assembled those capabilities into an integrated preclinical organization, offering translational animal models, CRO services and laboratory sciences from one accountable team. Sponsors working with the company typically begin at theHOME page to understand the service architecture, then narrow down to the specific platform their program needs. The result is a shorter path from protocol concept to a defensible data package.

Company and Capability Overview: One Integrated Preclinical Partner

HuaTeng Biotech operates as a one-stop preclinical research organization with facilities in Guangzhou and Hong Kong, serving pharmaceutical, biotechnology and medical device sponsors internationally. Its portfolio spans gene-edited, drug-induced, surgically induced and diet-induced in vivo models across both small and large animals, organized by body system so sponsors can navigate to cardiovascular, nervous, digestive, musculoskeletal and metabolic programs quickly. Behind that portfolio sits a team that includes surgeons, veterinarians, anesthesia specialists, imaging scientists, histopathologists and project managers, which means a study does not fragment across five vendors. The company also invests in the instrumentation that makes complex work measurable: fluoroscopy and interventional imaging, advanced surgical platforms, in vitro cell culture, molecular biology, quantitative bioanalysis, behavioral neuroscience and histopathology. Details of the organization, certifications and global partnerships are summarized on theAbout Us page. For sponsors, this concentration of capability matters because surgical model quality is inseparable from the quality of the supporting readouts.
Quality systems and project management are where preclinical partners are most often separated from one another, and this is an area HuaTeng Biotech treats as a core differentiator rather than an administrative afterthought. Studies are conducted under GLP-compliant workflows with AAALAC-accredited animal care, supported by standard operating procedures, controlled documentation, deviation handling and audit-ready records. Each program is assigned a project manager who functions as a single point of contact, coordinating protocol finalization, scheduling, surgical teams, imaging slots, sample logistics and reporting timelines so sponsors are not left chasing updates. Sponsor-facing workflows include protocol co-development, milestone-based reporting, interim data reviews and rapid escalation of clinical observations in life. TheCRO Servicesoverview describes how preclinical drug development, in vivo medical device testing, laboratory sciences and core R&D offerings connect into a single engagement. For programs with compressed timelines, that integration is frequently the difference between hitting a submission window and losing a quarter.

Core Model Portfolio: Pigs, Dogs, Sheep and Rabbits

The backbone of the large animal portfolio is a species set chosen for specific translational strengths rather than convenience. Swine are the default choice for cardiovascular, interventional and abdominal work because porcine coronary and peripheral anatomy, coagulation behavior and skin structure approximate human physiology closely, and because animals can be grown to human-like scale. Dogs remain valuable for orthopedic, spinal and certain cardiovascular and device studies where a well-characterized background and manageable size support chronic follow-up. Sheep are favored for orthopedic and cardiovascular valve or graft work thanks to docile temperament, robust bone quality and reliable tolerance of long-term instrumentation. Rabbits occupy a complementary niche in bone healing, ocular, wound and dental research where small size and rapid remodeling suit screening and mechanistic endpoints. The full catalog of species and disease models is organized on theAnimal Models page by system and induction method. Sponsors can therefore select a species on scientific grounds and then confirm feasibility, group sizes and endpoint plans with the surgical team early.
What distinguishes a capable provider is not the species list but the ability to execute demanding surgical procedures reproducibly at scale. Complex surgical models require instrumented anesthesia, meticulous hemostasis, sterile technique, appropriate analgesia and a recovery pathway that keeps animals stable through the chronic phase of a study. HuaTeng Biotech's surgical teams routinely deliver orthopedic, vascular, wound healing and peripheral artery disease procedures, along with interventional catheter-based work performed under imaging guidance. Each protocol is rehearsed against anatomical realities before the first animal is enrolled, because an unworkable access route discovered mid-study is expensive in animals, time and data integrity. Perioperative care, fluid management, pain scoring and daily veterinary rounds are documented as part of the record, not handled informally. That discipline is what allows a sponsor to compare outcomes across cohorts, across time points and, eventually, across study sites.
Interventional models deserve separate attention because they sit closest to the way human therapies are actually delivered. Catheter-based procedures in swine allow sponsors to test stent delivery, balloon angioplasty, thrombectomy devices, embolic agents, transcatheter valves, closure devices and drug-coated platforms under fluoroscopic guidance that mirrors a human catheterization laboratory. These interventional models combine surgical exposure with imaging-based navigation, which means the team must be fluent in both disciplines simultaneously. Vascular access, guidewire tracking, device deployment, contrast dosing and post-procedural angiography all have to be executed consistently so that performance differences reflect the device rather than the operator. Post-procedure endpoints typically include angiography, intravascular imaging, histology and biomarker sampling, and HuaTeng Biotech supports all of them within the same workflow. The company also builds peripheral artery disease and ischemic wound variants in which device or drug performance is judged against perfusion and tissue repair, not only vessel patency.
0

Specialized Surgical Modeling: Orthopedic, Vascular, Wound Healing and PAD

Specialized surgical modeling is where translational realism is won or lost, and it is the strongest practical argument for working with an experienced surgical CRO. Orthopedic in vivo models in sheep, dogs and rabbits can reproduce fracture fixation, bone defect healing, osteotomy, joint replacement, spinal fusion and cartilage repair, using implants and loading conditions that resemble clinical use. Vascular modeling covers patch angioplasty, bypass grafting, arteriovenous fistula creation, aneurysm creation and vessel injury models where neointimal response and endothelialization are the endpoints of interest. Wound healing studies benefit from species with human-like dermal architecture, enabling full-thickness excisional, burn, ischemic and infected wound protocols with planimetry, histology and tensile strength readouts. Peripheral artery disease modeling adds a metabolic and ischemic dimension, combining arterial occlusion or ligation with controlled exercise, diet or comorbid induction to test revascularization strategies and cellular therapies. Because these models are procedure-dependent, the surgical learning curve is a real variable, and partner selection should weigh case volume and technique standardization as heavily as species availability.

Gene-Edited Large Animal Customization

For programs that need a disease phenotype rather than an induced injury, gene-edited large animals offer a powerful and increasingly practical route. HuaTeng Biotech supports customization starting from species selection, weighing physiology, breeding capacity, generation interval and endpoint accessibility against the biology a sponsor wants to interrogate. Editing strategies can range from targeted knockouts and knock-ins to precise point mutations and humanized or reporter alleles, selected according to the phenotype required and the regulatory question being asked. Candidate design, editing efficiency assessment and founder screening are handled with documented molecular characterization before any animal enters a study. Because gene-edited large animals are living research assets, colony management, health monitoring and genetic stability become part of the scientific plan rather than a downstream concern. Sponsors receive documentation support suitable for internal review and regulatory dialogue, including lineage records and characterization reports. This is the capability that lets a sponsor study a human-relevant disease mechanism in an animal large enough for surgical instrumentation and clinical-grade imaging.
Phenotyping and scaling are the stages where gene-edited programs most often need experienced partners. Establishing a colony is one challenge; demonstrating that the resulting animals reliably express the intended phenotype, with appropriate penetrance and a usable onset window, is another and often harder one. HuaTeng Biotech builds phenotyping packages that combine clinical observations, functional testing, imaging, histopathology and molecular confirmation so the phenotype is characterized rather than assumed. Breeding and scaling plans are then aligned with study enrollment forecasts, so sponsors are not left waiting months for age- and genotype-matched cohorts. Where a program requires both an edited background and a surgical insult, the team can converge the two, which is a demanding but highly informative study design. Documentation, chain of custody and genetic records are maintained throughout so that data traceability survives audits and submissions. Early feasibility conversations are strongly recommended, because editing and breeding timelines, not surgical capacity, usually determine the critical path.

Competitive Advantages: Why Execution Quality Compounds

The competitive advantages that sponsors report most consistently come down to customization, surgical depth and coordination. Protocols are designed around the specific regulatory and scientific question rather than pulled from a menu, which frequently reduces animal numbers while improving endpoint relevance. Surgical expertise is in-house and deep, covering orthopedic, vascular, interventional, wound and ischemic procedures with standardized technique and documented anesthesia and analgesia protocols. Perioperative care, critical care capability and 24-hour veterinary oversight protect the chronic phase of a study, where attrition silently destroys statistical power. Imaging and endpoint support are integrated, spanning fluoroscopy, angiography, ultrasound, CT and MRI where appropriate, along with histopathology and biomarker analysis. Turnaround is fast because scheduling, surgery, imaging and analysis sit inside one organization instead of across contracted partners, and ethical compliance is embedded because review, welfare oversight and traceability are part of every protocol. Scalable delivery means a sponsor can move from a pilot feasibility cohort to a multi-cohort program without rebuilding the workflow.

Applications and Endpoints Across Therapeutic Areas

The application range of these in vivo models is broad, and it helps sponsors to see how endpoints map to their submission strategy. Medical device programs use large animal work for functional performance, biocompatibility, safety and surgical simulation, including simulated-use studies that inform instructions for use and training, with details on the Medical Device Testing In Vivo page. Biologics and small molecule programs use pharmacodynamic, pharmacokinetic and DMPK evaluation alongside GLP safety assessment in both small and large animals, described under Preclinical Drug Development SolutionsCell and gene therapy programs increasingly require large animal proof of concept, biodistribution and durable expression data before clinical entry. Tissue repair and regeneration studies rely on histological and biomechanical endpoints that demonstrate constructive remodeling rather than fibrous encapsulation. Cardiovascular and metabolic disease programs combine functional testing, imaging and biomarker panels to capture systemic effects. Across all of these, the deliverable is a data package that a reviewer, a regulatory body or an investor can interrogate, and theResources section documents the underlying platforms that make those readouts credible.

Quality, Ethics and Compliance as Design Inputs

Animal welfare, ethical review and data integrity are not constraints bolted onto a study at the end; they shape how a good study is designed from the first draft. HuaTeng Biotech operates AAALAC-accredited facilities with institutional animal care and use committee review, protocol-level justification of animal numbers, and continuous welfare monitoring by veterinary staff. Enrichment, anesthesia refinement, analgesia and humane endpoint criteria are written into protocols, and any clinical abnormality triggers documented review rather than informal observation. Traceability is maintained from animal identification through surgery, treatment, sample collection, storage and analysis, so that any data point can be reconstructed on request. Data integrity practices include controlled raw data handling, version-controlled protocols and amendments, and clear separation of study conduct from reporting review. Reproducibility is supported by standardized surgical technique, defined endpoint criteria and consistent operator training. Sponsors preparing for FDA, CE or NMPA submissions should expect to discuss these controls early, because reviewers increasingly ask for exactly this level of detail.

Model Selection Guide: Choosing the Right Species and Procedure

A disciplined selection process saves more time than any single technical optimization. For cardiovascular and interventional device work, swine usually lead because catheter navigation, vessel caliber and thrombogenicity resemble the clinical setting, and access sites support repeated procedures. For orthopedic and spinal studies, sheep and dogs offer bone size and load-bearing capacity that allow human-scale implants, while rabbits remain efficient for early bone healing and cartilage screening. For wound healing and dermal regeneration, species with human-like skin architecture and reliable planimetry access should be prioritized, and for ischemic or PAD work the model must include a credible perfusion deficit that can be measured serially. When a genetic component is essential, a gene-edited large animal may replace or complement an induced model, but the breeding timeline must enter the project plan from day one. Practical considerations also matter: animal availability within the enrollment window, imaging throughput, the number of procedures a single animal can ethically carry, and the endpoints that will actually persuade a reviewer. Sponsors who bring a draft protocol and a clear regulatory question to the first discussion typically leave with a species recommendation, a feasibility assessment and a realistic timeline in the same conversation.

Why Partner with HuaTeng Biotech

Choosing a preclinical partner is a multi-year decision, and the sensible criterion is whether the organization can carry a program from model design through reporting without handoffs that lose information. HuaTeng Biotech supports sponsors end to end: scoping the biological question, selecting species and procedure, drafting the protocol, running the surgical and interventional work, delivering imaging and histological endpoints, and producing a report that stands up to scrutiny. Programs that begin with a pilot feasibility cohort frequently scale into multi-cohort GLP-ready studies using the same teams, same facilities and same documentation standards, which removes a large source of variability. Communication is structured around a named project manager, scheduled milestone reviews and escalation paths that work at the speed programs actually move. For sponsors who need edited animals, complex surgical in vivo models or a combination of both, the company offers a single accountable pathway instead of a consortium of vendors. The fastest way to evaluate fit is a scoping conversation about the target tissue, the intended clinical use and the submission pathway, and the team can be reached through theContact Us page.

Conclusion: Translational Confidence Starts with the Model

Confidence in a clinical program is built long before the first patient is enrolled, and it is built in the model room. Species that mirror human anatomy, surgical teams that reproduce procedures consistently, welfare and quality systems that make data defensible, and gene-editing capability that can create a disease phenotype on demand are the raw materials of that confidence. HuaTeng Biotech has organized its platforms, people and documentation around exactly those requirements, which is why sponsors use its large animal in vivo models for device, biologic, cell and gene therapy programs that cannot afford ambiguous results. The company's combination of complex surgical modeling, interventional capability, orthopedic, vascular, wound and PAD expertise, and gene-edited large animal customization covers the full translational spectrum from feasibility to submission support. Programs are best started early, because animal availability, editing timelines and imaging capacity all benefit from advance planning rather than late acceleration. Sponsors ready to discuss a specific indication, device concept or edited phenotype can begin with a confidential scoping conversation throughContact Us, including locations in Guangzhou and Hong Kong.

Frequently Asked Questions (FAQ)

What are in vivo models, and why do large animals matter for preclinical programs?

In vivo models are living animal systems used to evaluate safety, performance and biological effect before human trials. Large animals matter because their anatomy, hemodynamics and tissue scale allow realistic device deployment and surgery that rodents cannot support. They also enable serial imaging, repeated blood sampling and chronic follow-up over weeks or months. For devices, biologics and cell therapies, that realism is often what regulators expect to see.

Can HuaTeng Biotech customize in vivo models for a specific device or indication?

Yes. Protocols are built around the clinical question rather than selected from a fixed catalog, covering species choice, surgical approach, group size, endpoint schedule and reporting format. Customization also extends to induction method, comorbidity, imaging strategy and analysis plan. Sponsors typically share a draft protocol or a brief description of the intended clinical use, and the team returns a feasibility assessment with recommendations. Where needed, edited backgrounds and surgical insults can be combined into a single designed model.

Which species are available, and how do I choose between pig, dog, sheep and rabbit?

The portfolio includes pigs, dogs, sheep, rabbits and other species suited to specific questions. Swine are preferred for cardiovascular, interventional and abdominal work, dogs and sheep for orthopedic and spinal studies at human scale, and rabbits for bone healing, ocular and wound screening. Selection should weigh anatomy, size, availability, endpoint accessibility and the regulatory question. An early species discussion usually resolves the decision faster than literature alone.

What kinds of complex surgical models can be delivered?

Capabilities span orthopedic fixation and bone defect models, vascular grafting and fistula creation, wound healing and ischemic wound protocols, and peripheral artery disease modeling with perfusion endpoints. Interventional catheter-based procedures are performed under fluoroscopic guidance for stent, valve, thrombectomy and embolic device evaluation. Each procedure includes instrumented anesthesia, perioperative critical care and documented pain management. Technique standardization is maintained so results remain comparable across cohorts.

How does gene-edited large animal customization work?

Customization begins with species and strategy selection, followed by editing design, founder screening and molecular characterization. Phenotyping then confirms that the intended disease features appear with usable penetrance and onset. Breeding and scaling plans are aligned to enrollment forecasts so age- and genotype-matched cohorts are available on schedule. Documentation including lineage and characterization records supports internal review and regulatory dialogue.

What is the typical timeline for an in vivo model study?

Timelines vary with procedure complexity, animal availability, endpoint duration and reporting scope, so a feasibility review is the reliable way to plan. Surgically induced models often progress from protocol finalization to first procedure within weeks, while chronic endpoints extend the calendar according to the follow-up period. Gene-edited programs are paced mainly by editing and breeding, which should be planned months ahead. Early engagement protects submission milestones more effectively than later acceleration.

Which endpoints and data packages are provided?

Endpoints typically combine functional performance testing, imaging such as fluoroscopy, angiography, ultrasound, CT or MRI, histopathology, and biomarker or pharmacokinetic analysis. Data are compiled into a report suitable for internal decision-making and regulatory submission support, with raw data traceability maintained. Interim data reviews can be scheduled for time-critical programs. Deliverables are defined during protocol development so there are no surprises at reporting.

How are animal welfare, ethics and compliance handled?

Studies run in AAALAC-accredited facilities under institutional animal care and use committee review, with protocol-level justification of animal numbers. Enrichment, anesthesia refinement, analgesia and humane endpoint criteria are documented, and clinical abnormalities trigger formal review. Documentation practices support GLP-compliant workflows, traceability and data integrity, which sponsors rely on for FDA, CE and NMPA submissions. Welfare oversight is continuous rather than episodic.

Do in vivo models support both medical device and drug development programs?

Yes. Device programs use large animal work for functional performance, biocompatibility and safety testing plus surgical simulation, while drug and biologic programs use pharmacodynamic, pharmacokinetic and GLP safety packages across small and large animals. Cell and gene therapy studies add biodistribution and durable expression endpoints. Because these services sit within one organization, sponsors can sequence device and drug work without rebuilding supplier relationships. This integration shortens the path to a coherent data package.
Contact
Leave your information and we will contact you.

Copyright ©️ 2022, NetEase Zhuyou(and its affiliates as applicable). All Rights Reserved.

Company

Collections

About

Follow us

Team&Conditions

Work With Us

Featured Products

News

LinkedIn

All products

Shop

Facebook

Twitter

phone
Email